Drug intelligence / Profile preview

Vonlerolizumab

Development stage: Phase 2
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Vonlerolizumab (also known as MOXR0916) is a humanized IgG1 agonistic monoclonal antibody that targets OX40 (Tumor Necrosis Factor Receptor Superfamily Member 4). It functions as an OX40 agonist, stimulating co-stimulatory signals in T cells, which is a mechanism relevant for cancer immunotherapy. Developed by Genentech, it was investigated for its potential in various solid tumors, including melanoma, renal cell carcinoma, non-small cell lung carcinoma, urothelial carcinoma, and triple-negative breast cancer. The drug was administered intravenously. Genentech has terminated its Phase 2 trial for urothelial carcinoma and discontinued further development of Vonlerolizumab.

Other names: vonlerolizumab

Targets

CD28 (Cluster of Differentiation 28)

Beyond the preview

Go deeper on Vonlerolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vonlerolizumab.

Explore the full profile